{
    "clinical_study": {
        "@rank": "83890", 
        "arm_group": [
            {
                "arm_group_label": "Active", 
                "arm_group_type": "Experimental", 
                "description": "Single escalating doses of TD-1607, administered intravenously"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "TD-1607, administered intravenously as single doses, will be investigated in healthy\n      subjects to assess its tolerability, safety, and pharmacokinetics."
        }, 
        "brief_title": "TD-1607 SAD Study in Healthy Subjects", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Serious Infections Due to Known or Suspected Gram-positive Pathogens", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is a healthy nonsmoking male or a female of non-child bearing potential and\n             18 to 50 years old, inclusive, at Screening.  Females are considered to be of\n             non-childbearing potential if they have had a hysterectomy or tubal ligation or are\n             postmenopausal (amenorrheic for at least 2 years) with a follicle-stimulating hormone\n             (FSH) level >20 IU/L.\n\n          -  Subject has a body mass index (BMI) of 19 to 30 kg/m2, inclusive, and weighs at least\n             50 kg\n\n        Exclusion Criteria:\n\n          -  Subject has evidence or history of clinically significant allergic (except for\n             untreated, asymptomatic seasonal allergies at time of dosing), hematological,\n             endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or\n             neurological disease.\n\n          -  Subject has a history of allergies or hypersensitivities to glycopeptide (e.g.,\n             vancomycin), penicillin, or cephalosporin antibiotics.\n\n          -  Subject has participated in another clinical trial of an investigational drug (or\n             medical device) within 60 days (or 5 half-lives, whichever is longer) prior to\n             Screening or is currently participating in another trial of an investigational drug\n             (or medical device)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01791049", 
            "org_study_id": "0098"
        }, 
        "intervention": [
            {
                "arm_group_label": "Active", 
                "intervention_name": "TD-1607", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Gram-positive", 
            "Infections", 
            "Bacterial infections"
        ], 
        "lastchanged_date": "December 3, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Austin", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78744"
                }, 
                "name": "PPD Phase 1"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double\u2212Blind, Placebo\u2212Controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD-1607, a Glycopeptide\u2212Cephalosporin Heterodimer Gram\u2212Positive Antibiotic, in Healthy Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Adverse events, laboratory abnormalities, ECGs, and vital sign measurements.", 
            "measure": "Safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "11 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01791049"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Cmax, Tmax, AUC0-t, AUC0-24, AUCinf, CL, Vdss, t1/2, amount excreted in urine (Ae), fraction eliminated in urine (fe), and CLr.", 
            "measure": "Pharmacokinetics", 
            "safety_issue": "No", 
            "time_frame": "96 hours"
        }, 
        "source": "Theravance, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Theravance, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}